Sector News

ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor

March 5, 2015
Life sciences
(GLOBE NEWSWIRE) – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of vitreo-retinal diseases, is pleased to announce that Joseph Markoff, Ph.D., M.D. has joined the Company as Scientific Advisor. Dr. Markoff will report to Paul G. Howes, Executive Chairman of ThromboGenics Inc., and work with the Medical Affairs team in the U.S. and the global Clinical Development team.
 
Dr. Markoff has over 35 years of experience as an ophthalmic surgeon at the Wills Eye Hospital in Philadelphia, PA. He has directed the hospital’s Visual Physiology service for the past 32 years and also holds the rank of Attending Surgeon and Clinical Professor of Ophthalmology at Thomas Jefferson University Medical School.
 
Dr. Markoff founded Philadelphia Eye Associates, a leading private eye care practice in the Philadelphia area. From February 2010 till recently, he assumed the role as Global Director for Scientific Affairs in Ophthalmology at Merck & Co., Inc.
 
Dr. Markoff has conducted over 50 clinical trials during his career sponsored by companies such as Alcon, Allergan, Pfizer, Pharmacia and Merck & Co.
 
Paul Howes, Executive Chairman of ThromboGenics, Inc. said: “Joseph Markoff adds vast experience and knowledge in ophthalmology, particularly in the retinal space, to the ThromboGenics team. I expect his expertise to prove hugely valuable as we roll-out the results of on-going real-world clinical studies on treatment of symptomatic VMA with JETREA® and embark on new indications such as diabetic retinopathy.”
 
Source: ThromboGenics

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend